Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged

Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged is offered by Tachlit, a leading player in the field of passive investments.

The total expense ratio of Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged is 0.3%, which means that investors pay 30 ILS per 10,000 ILS in investment capital annually.

The ETF is listed in ILS.

European investors may incur additional costs for currency exchange and transaction fees.

No, Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged does not comply with the EU UCITS investor protection directives.

Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged tracks the performance of the NASDAQ Biotechnology Index.

Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged is domiciled in IL.

The fund was launched on 11/27/2018.

The Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged mainly invests in Healthcare companies.

The NAV of Tachlit SAL (4A) NASDAQ Biotechnology Currency-Hedged amounts to 30.55 M ILS.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.